CorrGene
Nanjing
About CorrGene
CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $15.7M
- Funding stage: Seed
- Last round: Seed (Feb 2022)
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/corrgene-130385 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.